Journals / İstanbul Üniversitesi İstanbul Tıp Fakültesi Mecmuası / 2004 / Cilt: 67 - Sayı: 4

Biochemical markers of liver fibrosis in patients with chronic viral liver disase

Viral etiyolojili kronik karaciğer hastalarında karaciğer fibrozisi için biyokimyasal göstergeler

Pages
229–235
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

According to our results, it should be considered that serum hyaluronat levels may be used as a noninvasive marker for diagnosis of chirrosis or severe fibrosis in viral liver disease.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Liver biopsy is the gold standard for the diagnosis of chronic viral liver disease.
📊
Key Findings & Data:The aim of our study is to determine the diagnostic accuracy of serum hyaluronat and procollagen III N-terminal peptide (PIIINP) levels for the evaluation of liver fibrosis in chronic viral liver disease. 183 chronic hepatitis patients with viral etiology were included in our study (112 male, mean 44.4±13.7 year) and liver biopsy and/or laparoscopy were done in each.
💡
Conclusion & Impact:According to our results, it should be considered that serum hyaluronat levels may be used as a noninvasive marker for diagnosis of chirrosis or severe fibrosis in viral liver disease.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Liver biopsy is the gold standard for the diagnosis of chronic viral liver disease. Because liver biopsy is an invasive procedure, development of noninvasive biochemical markers reflecting liver fibrosis is a necessity. The aim of our study is to determine the diagnostic accuracy of serum hyaluronat and procollagen III N-terminal peptide (PIIINP) levels for the evaluation of liver fibrosis in chronic viral liver disease. 183 chronic hepatitis patients with viral etiology were included in our study (112 male, mean 44.4±13.7 year) and liver biopsy and/or laparoscopy were done in each. When the values of "the area under the receiver operating characteristic (AUROC)" were calculated, they were found to be 0.892 + 0.027 for hyaluronat and 0.658 + 0.048 for PII¬INP in seperence cirrhosis. The diagnostic accuracy of serum hyaluronate and PIIINP for se¬vere fibrosis (F3-F4) were 76% (cut-off value, 60 ng/ml) and 53.7% (cut-off value, 6.4 ug/1) and for cirrhosis were 75.2% (cut-off value, 60 ng/ml) and 60.5% (cut-off value, 6.4 ug/1) respectively. According to our results, it should be considered that serum hyaluronat levels may be used as a noninvasive marker for diagnosis of chirrosis or severe fibrosis in viral liver disease.

Özet

Karaciğer biyopsisi, kronik karaciğer hastalığının tanısında altın standarttır. Ancak biyopsinin invaziv bir işlem olması, karaciğer fibrozisini yansıtan noninvaziv biyokimyasal göstergelerin geliştirilmesini zorunlu kılmaktadır. Çalısmamızın amacı, viral etiyolojili kronik karaciğer hastaliğinda serum hyaluronat ve prokollajen III N-terminal peptid (PIIINP) düzeylerinin karaciger fibrozisini gostermedeki tanısal doğruluğunu saptamaktır. Çalışmaya viral etiyolojili 183 kronik hepatitli hasta alındı (112 erkek, ortalama yaş 44.4±13.7 yil) ve hepsine karaciger ponksiyon biyopsisi ve/veya laparoskopi yapıldı. ROC eğrileri ile hesaplandığında "the area under the receiver operating characteristic (AUROC)" degerleri, sirozu gb'stermede hyaluronat icin 0.892 ± 0.027, PIIINP icin 0.658 ± 0.048 olarak bulundu. ileri fibrozisi (F3-F4) saptama-da tanisal dogruluk oranlan hyaluronat icin (eşik deger 60 ng/ml) %76, PIIINP igin (eşik deger 6.4 ug/1) %53.7, sirozu saptamada tanısal dogruluk oranlan hyaluronat icin (e§ik deger 100 ng/ml) %75.2, PIIINP icin (esjk deger 6.4 ug/1) %60.5 saptandi. Sonuçlanmış serum hyaluronat düzeylerinin viral etiyolojili karaciger sirozunun veya ileri fibrozisinin tanısında noninvaziv bir gösterge olarak kullanılabileceği düşündürmektedir.

🔖

Cite This Article

AKSÖZEK, A., ÇEVİKBAŞ, U., AYDIN, Z., AKYÜZ, F., DEMİR, K., BEŞIŞIK, F., ÖKTEN, A., MUNGAN, Z., ÇAKALOĞLU, Y., BOZTAŞ, G., ÖZDİL, S., KÖROĞLU, G., DANALIOĞLU, A., KAYMAKOĞLU, S. (2022). Biochemical markers of liver fibrosis in patients with chronic viral liver disase. İstanbul Üniversitesi İstanbul Tıp Fakültesi Mecmuası, Cilt: 67 - Sayı: 4, 229–235. https://ajindex.com/articles/553674

References (14)

  1. Perrillo RP: The role of liver biopsy in hepatitis C. Hepatology; 1997; 26:57
  2. EASL International Consensus Conference on Hepatitis C: Paris, February 26-27, 1999. Consensus statement. J Hepatol; 1999; 31: 3
  3. Cadranel JF, Rufat P, Degos F: Practices of liver biopsy in France:results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology; 2000; 32: 477
  4. Froehlich F, Lamy O, Fried M, Gonvers JJ: Practice and complications of liver biopsy. Results of a nationwide survey in Switzerland. Dig Dis Sci; 1993; 38: 1480
  5. McGill DB, Rakela J, Zinsmeister AR, Ott BJ: A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology; 1990; 99: 1396
  6. Oberti F, Valsesia E, Pilette C et al: Noninvazive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology; 1997; 113: 1609
  7. Tran A, Hastier P, Barjoan EM et al: Non invasive prediction of severe fibrosis in patients with alcoholic liver disease. Gastroenterol Clin Biol.; 2000; 24: 626
  8. Leroy V, Traversay C, Barnoud R et al: Changes in histological lesions and serum fibrogenesis markers in chronic hepatitis C patients non-responders to interferon- ?. J Hepatol.; 2001; 35:120
  9. Ishibashi K, Kashiwagi T, Ito A et al: Changes in serum fibrogenesis markers during interferon therapy for chronic heaptitis type C. Hepatology; 1996; 1: 27
  10. Murawaki Y, Ikuta Y, Okamoto K et al: Diagnostic value of serum markers of connective tissue turnover for predicting histological staging and grading in patients with chronic hepatitis C. J Gastroenterol; 2001; 6: 399
  11. Myers RP, Ratziu V, Imbert-Bismut F, Charlotte F, Poynard T: Biochemical markers of liver fivrosis: A comparison with historical features in patients with chronic hepatitis C. The MULTIVIRC group. Am J Gastroenterol; 2002; 97:2419
  12. Myers RP, De Torres M, Imbert-Bismut F, Ratziu V, Charlotte F, Poynard T: Biochemical markers of fibrosis in patients with chronic hepatitis C. The MULTIVIRC group. Dig Dis Sci; 42003; 8: 146
  13. Lu LG, Zeng MD, Wan MB, Li CZ, Mao YM, Li JQ, Qiu DK, Cao AP, Ye J, Cai X, Chen CW, Wang JY, Wu SM, Zhu JS, Zhou XQ: Grading and staging of hepatic fibrosis, and its relationship with noninvasive diagnostic parameters. World J Gastroenterol; 2003; 9: 2574
  14. Ramadori G, Zoehrens G, Manns MP, Rider H, Dienes HP, Hess G, Meyer-z. Bueschenfelde KH: Serum hyaluronate and type III procollagen aminoterminal propept